Seres Therapeutics (MCRB) Tops Q1 EPS by 3c

Seres Therapeutics (NASDAQ: MCRB) reported Q1 EPS of ($0.63), $0.03 better than the analyst estimate of ($0.66). Revenue for the quarter came in at $3.02 million versus the consensus estimate of $2.3 million.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Cerebras Systems posts 94% revenue jump, announces OpenAI deal